Lurbinectedin for the treatment of small cell lung cancer

Li，L.1; Zou，C.2; Dong，S.2; Wu，Z. X.3; Ashby，C. R.3; Chen，Z. S.3; Qiu，C.1

2021-06-01

10.1358/dot.2021.57.6.3294559

DRUGS OF TODAY   影响因子和分区

1699-3993

1699-4019

Small cell lung cancer (SCLC) is a rapidly progressive, aggressive metastatic and lethal subtype of lung cancer. Unfortunately, there has been little progress regarding the development of novel treatments for SCLC. However, lurbinectedin, a transcriptional inhibitor, has emerged as a potential novel treatment for cancer. It produces antitumor efficacy by inhibiting oncogenic transcription activity, inducing the accumulation of DNA double-strand breaks and modulating the tumor microenvironment (TME). Data from phase I/II trials indicates that lurbinectedin has significant antitumor efficacy and tolerable adverse effects in SCLC patients. Furthermore, lurbinectedin is efficacious in platinum-sensitive and platinumresistant SCLC patients and in those with SCLC relapse after second-line treatment. In 2020, the U.S. Food and Drug Administration (FDA) approved lurbinectedin for the treatment of adult patients with metastatic SCLC or for patients that have received platinum-based chemotherapy. In this review, we discuss the molecular profile and the preclinical and clinical studies of lurbinectedin in the treatment of SCLC patients.

Antitumor drugs DNA alkylating drugs Lurbinectedin RNA polymerase II inhibitors Small cell lung cancer (SCLC) Transcription inhibitors Tumor microenvironment (TME)

SCI

英语

第一 ; 通讯

WOS:000662217200002

2-s2.0-85108159825

Scopus

1.Key Laboratory of Shenzhen Respiratory Diseases,Institute of Respiratory Disease,Second Affiliated Hospital of Jinan University,First Affiliated Hospital,Southern University of Science and Technology,Shenzhen People's Hospital,Shenzhen,China
2.Clinical Research Center,Second Affiliated Hospital of Jinan University,First Affiliated Hospital,Southern University of Science and Technology,Shenzhen People's Hospital,Shenzhen,China
3.Department of Pharmaceutical Sciences,College of Pharmacy and Health Sciences,St. John's University,Queens,11439,United States

Li，L.,Zou，C.,Dong，S.,et al. Lurbinectedin for the treatment of small cell lung cancer[J]. DRUGS OF TODAY,2021,57(6):377-385.

Li，L..,Zou，C..,Dong，S..,Wu，Z. X..,Ashby，C. R..,...&Qiu，C..(2021).Lurbinectedin for the treatment of small cell lung cancer.DRUGS OF TODAY,57(6),377-385.

Li，L.,et al."Lurbinectedin for the treatment of small cell lung cancer".DRUGS OF TODAY 57.6(2021):377-385.